crizotinib and Lymphoma--Primary-Effusion

Kaposi sarcoma-associated herpesvirus (KSHV) is a principal causative agent of primary effusion lymphoma (PEL) with a poor prognosis in immunocompromised patients. However, it still lacks effective treatment which urgently requires the identification of novel therapeutic targets for PEL. Here, we report that the hepatocyte growth factor (HGF)/c-MET pathway is highly activated by KSHV in vitro and in vivo. The selective c-MET inhibitor, PF-2341066, can induce PEL apoptosis through cell cycle arrest and DNA damage, and suppress tumor progression in a xenograft murine model. By using microarray analysis, we identify many novel genes that are potentially controlled by HGF/c-MET within PEL cells. One of the downstream candidates, ribonucleoside-diphosphate reductase subunit M2 (RRM2), also displays the promising therapeutic value for PEL treatment. Our findings provide the framework for development of HGF/c-MET-focused therapy and implementation of clinical trials for PEL patients.

Topics: Adult; Animals; Apoptosis; Cell Cycle Checkpoints; Comet Assay; Crizotinib; DNA Damage; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Hepatocyte Growth Factor; Herpesviridae Infections; Herpesvirus 8, Human; Humans; Immunoblotting; Immunocompromised Host; Lymphoma, Primary Effusion; Male; Mice; Mice, SCID; Middle Aged; Oligonucleotide Array Sequence Analysis; Piperidines; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Xenograft Model Antitumor Assays; Young Adult